CPT1C and neoplasm: Upon encountering ROS in the TME, the anti-VEGFR2 antibodies, CPT1C siRNA and 2-Deoxy-D-glucose are released, inhibiting angiogenesis, fatty acid oxidation and glycolysis pathways, killing the tumor cells by effectively blocking their energy supply [272].